English
简体中文
Total: £ 56.28
Published Date: 2026-01-13 | Pages: 147 | Tables: 139 | Medical Devices & Consumables
The global Drug Labels market was valued at US$ 2013 million in 2025 and is anticipated to reach US$ 2697 million by 2032, at a CAGR of 4.3% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Drug Labels competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Drug Labels are critical identification and compliance carriers used throughout a medicine’s lifecycle to communicate regulated information, support safe dispensing and use, and enable traceability and anti-counterfeit controls across distribution channels. Applied to primary-contact and secondary packaging (e.g., bottles, vials, blister packs, cartons, and shipping units), they typically carry the product name and strength, composition, batch/lot and expiry, marketing authorization and manufacturer details, storage conditions, warnings, and machine-readable elements such as barcodes/2D codes, serialization identifiers, and track-and-trace data. They solve the core problem of ensuring the right medicine, in the right form and strength, from the right batch and source, reaches the right destination—reducing dispensing errors, enabling efficient recalls, and providing audit-ready compliance across complex, multi-party supply chains. Historically, drug labeling evolved from basic text identifiers to standardized printed labels aligned with modern pharmaceutical manufacturing and quality systems; barcodes later added batch-level logistics visibility, and more recently serialization, tamper evidence, and anti-counterfeit requirements transformed drug labels into integrated “variable data + verification” systems connected to packaging lines and enterprise logistics platforms. Depending on risk and value, solutions may incorporate tamper-evident constructions, covert/overt security features, and RFID/NFC or digital verification methods. Upstream supply commonly includes facestocks and constructions (pharmaceutical-grade papers, coated papers, synthetic papers, PP/PET films, specialty substrates for durability and low-temperature performance, often with barrier or abrasion-resistant coatings), pressure-sensitive adhesives (low-migration/low-extractable formulations; solvent/condensation resistant; permanent or removable for glass/plastics/metal), release liners, inks and varnishes (low-migration ink systems, scuff-resistant protective varnishes, compliant coatings), variable-data consumables (thermal-transfer ribbons and other coding materials), and packaging/inspection components (printheads, sensors, vision inspection cameras, barcode scan modules, serialization controllers, and RFID inlays/antenna/chips), collectively enabling validated compliance, readability, durability, and traceability.In 2025, global drug label production capacity reached 100 billion units, while sales volume amounted to 87.5 billion units. The average unit price was USD 0.023 per label, and corporate gross margins generally ranged between 20% and 30%.
The drug label market today is shaped by strict compliance requirements, stronger end-to-end coordination, and rising barriers in both quality management and data governance. Pharmaceutical manufacturers and CMOs/CDMOs increasingly treat labels as controlled packaging components rather than simple print purchases, emphasizing version control, change management, lot-level consistency, traceable records, and tight linkage with packaging lines, warehousing, and distribution systems. Regulatory, language, warning, and coding differences across countries drive multi-version, multi-language, and multi-template operations for the same product, raising complexity; at the same time, more frequent label changes and smaller, specialized runs—often seen in clinical and niche therapies—sustain demand for variable data and agile production. On the supply side, capabilities are stratifying: some providers win on validated processes, audit readiness, and cross-site delivery reliability, while others compete on flexibility and local responsiveness but face increasing scrutiny over quality systems, data discipline, and information security. As traceability and anti-counterfeit expectations grow, labeling becomes part of enterprise risk management, and buyer decisions increasingly weigh supply continuity, substitution qualification practices, and governance maturity.
Future development is likely to center on deeper data governance, stronger automation and in-line verification, and parallel upgrades in security and sustainability. On the content layer, drug labels will be more tightly anchored to master data platforms and regulatory rule libraries, using standardized templates, automated composition, multi-language consistency checks, approval workflows, and electronic signatures to reduce human error and prevent high-risk issues such as missing fields, inconsistent text, or layout deviations. Serialization and traceability data will become more tightly coupled with packaging-line controls, logistics systems, and downstream verification, enabling faster exception handling and more effective recall execution. Operationally, agile, short-lead-time production and variable data will remain important, but expectations will rise for real-time visual inspection, barcode grading, and robust electronic batch records that shift quality assurance from sampling toward continuous verification. Security features—tamper evidence, variable security printing, digital verification, and selective RFID/NFC—will continue to expand, typically following a “high-risk/high-value first, scale when workflow value is proven” path. Materials improvements (low-migration systems, chemical and wipe resistance, and more sustainability-aligned constructions) will progress, but only where they do not compromise compliance and readability.
Key drivers include regulatory and audit pressure, global supply-chain risk, and manufacturers’ sensitivity to operational disruption and brand exposure. Label errors can trigger recalls, enforcement actions, and patient-safety events, pushing investment in stronger governance, validated implementation, and more dependable supply partners. Ongoing volatility and multi-site manufacturing/distribution encourage dual sourcing, alternative-material strategies, and routine qualification and monitoring processes. The obstacles are largely about cross-functional alignment and implementation complexity: differing priorities and ownership boundaries across regulatory, quality, packaging engineering, supply chain, IT, and market access can prevent standardization, version convergence, and closed-loop change control; inconsistent master data across systems, uneven plant/line capabilities, and variability among outsourced partners in information security and record integrity extend timelines and increase coordination cost. Upstream material and component fluctuations lengthen qualification cycles, regional regulatory and language requirements fragment versions, and anti-counterfeit choices require trade-offs among cost, verifiability, and user experience—pushing the industry toward incremental upgrades rather than wholesale redesign. Programs tend to succeed when compliance is translated into executable processes, governance is embedded in systems and daily operations, and ongoing maintenance and audit readiness are treated as continuous disciplines rather than one-time projects.
This report delivers a comprehensive overview of the global Drug Labels market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Drug Labels. The Drug Labels market size, estimates, and forecasts are provided in terms of sales volume (K Pcs) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Drug Labels market comprehensively. Regional market sizes by Type, by Application, by Technology Type, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Drug Labels manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
PDC (Brady)
3M
RR Donnelley & Sons (RRD)
LabTAG
Tapecon
Avery Dennison
CCL Industries
CCL Healthcare
Multi-Color Corporation (MCC)
Autajon Group
Smurfit Westrock
Xerafy
Cymmetrik
Schreiner Group (Schreiner MediPharm)
SATO Holdings
DYMO Corporation
Nosco
Resource Label Group
Royal Label
PRO-TECH Design
Imprint Enterprises
JN White
Suzhou Thunder Weiye Information Technology Co., Ltd.
Zaosin
Segment by Type
Paper Label
Plastic Label
Composite Material Label
Special Material Label
Segment by Technology Type
Thermal Transfer Labels
Cryogenic Labels
Chemical-Resistant Labels
Others
Segment by Adhesive Type
Permanent Adhesives
Removable Adhesives
by Application
Pharmaceutical Factory
Hospital
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Technology Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Drug Labels manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Drug Labels sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Drug Labels Market Overview
1.1 Product Definition
1.2 Drug Labels by Type
1.2.1 Global Drug Labels Market Value by Type: 2025 vs 2032
1.2.2 Paper Label
1.2.3 Plastic Label
1.2.4 Composite Material Label
1.2.5 Special Material Label
1.3 Drug Labels by Technology Type
1.3.1 Global Drug Labels Market Value by Technology Type: 2025 vs 2032
1.3.2 Thermal Transfer Labels
1.3.3 Cryogenic Labels
1.3.4 Chemical-Resistant Labels
1.3.5 Others
1.4 Drug Labels by Adhesive Type
1.4.1 Global Drug Labels Market Value by Adhesive Type: 2025 vs 2032
1.4.2 Permanent Adhesives
1.4.3 Removable Adhesives
1.5 Drug Labels by Application
1.5.1 Global Drug Labels Market Value by Application: 2025 vs 2032
1.5.2 Pharmaceutical Factory
1.5.3 Hospital
1.5.4 Others
1.6 Global Drug Labels Market Size Estimates and Forecasts
1.6.1 Global Drug Labels Revenue 2021–2032
1.6.2 Global Drug Labels Sales 2021–2032
1.6.3 Global Drug Labels Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Drug Labels Market Competition by Manufacturers
2.1 Global Drug Labels Sales Market Share by Manufacturers (2021–2026)
2.2 Global Drug Labels Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Drug Labels Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Drug Labels, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Drug Labels, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Drug Labels, Product Types and Applications
2.7 Global Key Manufacturers of Drug Labels, Date of Entry into the Industry
2.8 Global Drug Labels Market Competitive Situation and Trends
2.8.1 Global Drug Labels Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Drug Labels Players Market Share by Revenue
2.8.3 Global Drug Labels Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drug Labels Market Scenario by Region
3.1 Global Drug Labels Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Drug Labels Sales by Region: 2021–2032
3.2.1 Global Drug Labels Sales by Region: 2021–2026
3.2.2 Global Drug Labels Sales by Region: 2027–2032
3.3 Global Drug Labels Revenue by Region: 2021–2032
3.3.1 Global Drug Labels Revenue by Region: 2021–2026
3.3.2 Global Drug Labels Revenue by Region: 2027–2032
3.4 North America Drug Labels Market Facts & Figures by Country
3.4.1 North America Drug Labels Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Drug Labels Sales by Country (2021–2032)
3.4.3 North America Drug Labels Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Drug Labels Market Facts & Figures by Country
3.5.1 Europe Drug Labels Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Drug Labels Sales by Country (2021–2032)
3.5.3 Europe Drug Labels Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drug Labels Market Facts & Figures by Region
3.6.1 Asia Pacific Drug Labels Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Drug Labels Sales by Region (2021–2032)
3.6.3 Asia Pacific Drug Labels Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Drug Labels Market Facts & Figures by Country
3.7.1 Latin America Drug Labels Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Drug Labels Sales by Country (2021–2032)
3.7.3 Latin America Drug Labels Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drug Labels Market Facts & Figures by Country
3.8.1 Middle East and Africa Drug Labels Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Drug Labels Sales by Country (2021–2032)
3.8.3 Middle East and Africa Drug Labels Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Drug Labels Sales by Type (2021–2032)
4.1.1 Global Drug Labels Sales by Type (2021–2026)
4.1.2 Global Drug Labels Sales by Type (2027–2032)
4.1.3 Global Drug Labels Sales Market Share by Type (2021–2032)
4.2 Global Drug Labels Revenue by Type (2021–2032)
4.2.1 Global Drug Labels Revenue by Type (2021–2026)
4.2.2 Global Drug Labels Revenue by Type (2027–2032)
4.2.3 Global Drug Labels Revenue Market Share by Type (2021–2032)
4.3 Global Drug Labels Price by Type (2021–2032)
5 Segment by Application
5.1 Global Drug Labels Sales by Application (2021–2032)
5.1.1 Global Drug Labels Sales by Application (2021–2026)
5.1.2 Global Drug Labels Sales by Application (2027–2032)
5.1.3 Global Drug Labels Sales Market Share by Application (2021–2032)
5.2 Global Drug Labels Revenue by Application (2021–2032)
5.2.1 Global Drug Labels Revenue by Application (2021–2026)
5.2.2 Global Drug Labels Revenue by Application (2027–2032)
5.2.3 Global Drug Labels Revenue Market Share by Application (2021–2032)
5.3 Global Drug Labels Price by Application (2021–2032)
6 Key Companies Profiled
6.1 PDC (Brady)
6.1.1 PDC (Brady) Company Information
6.1.2 PDC (Brady) Description and Business Overview
6.1.3 PDC (Brady) Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 PDC (Brady) Drug Labels Product Portfolio
6.1.5 PDC (Brady) Recent Developments/Updates
6.2 3M
6.2.1 3M Company Information
6.2.2 3M Description and Business Overview
6.2.3 3M Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 3M Drug Labels Product Portfolio
6.2.5 3M Recent Developments/Updates
6.3 RR Donnelley & Sons (RRD)
6.3.1 RR Donnelley & Sons (RRD) Company Information
6.3.2 RR Donnelley & Sons (RRD) Description and Business Overview
6.3.3 RR Donnelley & Sons (RRD) Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 RR Donnelley & Sons (RRD) Drug Labels Product Portfolio
6.3.5 RR Donnelley & Sons (RRD) Recent Developments/Updates
6.4 LabTAG
6.4.1 LabTAG Company Information
6.4.2 LabTAG Description and Business Overview
6.4.3 LabTAG Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 LabTAG Drug Labels Product Portfolio
6.4.5 LabTAG Recent Developments/Updates
6.5 Tapecon
6.5.1 Tapecon Company Information
6.5.2 Tapecon Description and Business Overview
6.5.3 Tapecon Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Tapecon Drug Labels Product Portfolio
6.5.5 Tapecon Recent Developments/Updates
6.6 Avery Dennison
6.6.1 Avery Dennison Company Information
6.6.2 Avery Dennison Description and Business Overview
6.6.3 Avery Dennison Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Avery Dennison Drug Labels Product Portfolio
6.6.5 Avery Dennison Recent Developments/Updates
6.7 CCL Industries
6.7.1 CCL Industries Company Information
6.7.2 CCL Industries Description and Business Overview
6.7.3 CCL Industries Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 CCL Industries Drug Labels Product Portfolio
6.7.5 CCL Industries Recent Developments/Updates
6.8 CCL Healthcare
6.8.1 CCL Healthcare Company Information
6.8.2 CCL Healthcare Description and Business Overview
6.8.3 CCL Healthcare Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 CCL Healthcare Drug Labels Product Portfolio
6.8.5 CCL Healthcare Recent Developments/Updates
6.9 Multi-Color Corporation (MCC)
6.9.1 Multi-Color Corporation (MCC) Company Information
6.9.2 Multi-Color Corporation (MCC) Description and Business Overview
6.9.3 Multi-Color Corporation (MCC) Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Multi-Color Corporation (MCC) Drug Labels Product Portfolio
6.9.5 Multi-Color Corporation (MCC) Recent Developments/Updates
6.10 Autajon Group
6.10.1 Autajon Group Company Information
6.10.2 Autajon Group Description and Business Overview
6.10.3 Autajon Group Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Autajon Group Drug Labels Product Portfolio
6.10.5 Autajon Group Recent Developments/Updates
6.11 Smurfit Westrock
6.11.1 Smurfit Westrock Company Information
6.11.2 Smurfit Westrock Description and Business Overview
6.11.3 Smurfit Westrock Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Smurfit Westrock Drug Labels Product Portfolio
6.11.5 Smurfit Westrock Recent Developments/Updates
6.12 Xerafy
6.12.1 Xerafy Company Information
6.12.2 Xerafy Description and Business Overview
6.12.3 Xerafy Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Xerafy Drug Labels Product Portfolio
6.12.5 Xerafy Recent Developments/Updates
6.13 Cymmetrik
6.13.1 Cymmetrik Company Information
6.13.2 Cymmetrik Description and Business Overview
6.13.3 Cymmetrik Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Cymmetrik Drug Labels Product Portfolio
6.13.5 Cymmetrik Recent Developments/Updates
6.14 Schreiner Group (Schreiner MediPharm)
6.14.1 Schreiner Group (Schreiner MediPharm) Company Information
6.14.2 Schreiner Group (Schreiner MediPharm) Description and Business Overview
6.14.3 Schreiner Group (Schreiner MediPharm) Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Schreiner Group (Schreiner MediPharm) Drug Labels Product Portfolio
6.14.5 Schreiner Group (Schreiner MediPharm) Recent Developments/Updates
6.15 SATO Holdings
6.15.1 SATO Holdings Company Information
6.15.2 SATO Holdings Description and Business Overview
6.15.3 SATO Holdings Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 SATO Holdings Drug Labels Product Portfolio
6.15.5 SATO Holdings Recent Developments/Updates
6.16 DYMO Corporation
6.16.1 DYMO Corporation Company Information
6.16.2 DYMO Corporation Description and Business Overview
6.16.3 DYMO Corporation Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 DYMO Corporation Drug Labels Product Portfolio
6.16.5 DYMO Corporation Recent Developments/Updates
6.17 Nosco
6.17.1 Nosco Company Information
6.17.2 Nosco Description and Business Overview
6.17.3 Nosco Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Nosco Drug Labels Product Portfolio
6.17.5 Nosco Recent Developments/Updates
6.18 Resource Label Group
6.18.1 Resource Label Group Company Information
6.18.2 Resource Label Group Description and Business Overview
6.18.3 Resource Label Group Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Resource Label Group Drug Labels Product Portfolio
6.18.5 Resource Label Group Recent Developments/Updates
6.19 Royal Label
6.19.1 Royal Label Company Information
6.19.2 Royal Label Description and Business Overview
6.19.3 Royal Label Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Royal Label Drug Labels Product Portfolio
6.19.5 Royal Label Recent Developments/Updates
6.20 PRO-TECH Design
6.20.1 PRO-TECH Design Company Information
6.20.2 PRO-TECH Design Description and Business Overview
6.20.3 PRO-TECH Design Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 PRO-TECH Design Drug Labels Product Portfolio
6.20.5 PRO-TECH Design Recent Developments/Updates
6.21 Imprint Enterprises
6.21.1 Imprint Enterprises Company Information
6.21.2 Imprint Enterprises Description and Business Overview
6.21.3 Imprint Enterprises Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Imprint Enterprises Drug Labels Product Portfolio
6.21.5 Imprint Enterprises Recent Developments/Updates
6.22 JN White
6.22.1 JN White Company Information
6.22.2 JN White Description and Business Overview
6.22.3 JN White Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 JN White Drug Labels Product Portfolio
6.22.5 JN White Recent Developments/Updates
6.23 Suzhou Thunder Weiye Information Technology Co., Ltd.
6.23.1 Suzhou Thunder Weiye Information Technology Co., Ltd. Company Information
6.23.2 Suzhou Thunder Weiye Information Technology Co., Ltd. Description and Business Overview
6.23.3 Suzhou Thunder Weiye Information Technology Co., Ltd. Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.23.4 Suzhou Thunder Weiye Information Technology Co., Ltd. Drug Labels Product Portfolio
6.23.5 Suzhou Thunder Weiye Information Technology Co., Ltd. Recent Developments/Updates
6.24 Zaosin
6.24.1 Zaosin Company Information
6.24.2 Zaosin Description and Business Overview
6.24.3 Zaosin Drug Labels Sales, Revenue, and Gross Margin (2021–2026)
6.24.4 Zaosin Drug Labels Product Portfolio
6.24.5 Zaosin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drug Labels Industry Chain Analysis
7.2 Drug Labels Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drug Labels Production Mode & Process Analysis
7.4 Drug Labels Sales and Marketing
7.4.1 Drug Labels Sales Channels
7.4.2 Drug Labels Distributors
7.5 Drug Labels Customer Analysis
8 Drug Labels Market Dynamics
8.1 Drug Labels Industry Trends
8.2 Drug Labels Market Drivers
8.3 Drug Labels Market Challenges
8.4 Drug Labels Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Drug Labels Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Drug Labels Market Value by Technology Type (US$ Million), 2025 vs 2032
Table 3. Global Drug Labels Market Value by Adhesive Type (US$ Million), 2025 vs 2032
Table 4. Global Drug Labels Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Drug Labels Market Competitive Situation by Manufacturers in 2025
Table 6. Global Drug Labels Sales (K Pcs) of Key Manufacturers (2021–2026)
Table 7. Global Drug Labels Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Drug Labels Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Drug Labels Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Drug Labels Average Price (US$/Pc) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Drug Labels, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Drug Labels, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Drug Labels, Product Types and Applications
Table 14. Global Key Manufacturers of Drug Labels, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Drug Labels Companies by Tier (Tier 1, Tier 2, Tier 3), based on Drug Labels Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Drug Labels Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Drug Labels Sales by Region (K Pcs), 2021–2026
Table 20. Global Drug Labels Sales Market Share by Region (2021–2026)
Table 21. Global Drug Labels Sales by Region (K Pcs), 2027–2032
Table 22. Global Drug Labels Sales Market Share by Region (2027–2032)
Table 23. Global Drug Labels Revenue by Region (US$ Million), 2021–2026
Table 24. Global Drug Labels Revenue Market Share by Region (2021–2026)
Table 25. Global Drug Labels Revenue by Region (US$ Million), 2027–2032
Table 26. Global Drug Labels Revenue Market Share by Region (2027–2032)
Table 27. North America Drug Labels Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Drug Labels Sales by Country (K Pcs), 2021–2026
Table 29. North America Drug Labels Sales by Country (K Pcs), 2027–2032
Table 30. North America Drug Labels Revenue by Country (US$ Million), 2021–2026
Table 31. North America Drug Labels Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Drug Labels Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Drug Labels Sales by Country (K Pcs), 2021–2026
Table 34. Europe Drug Labels Sales by Country (K Pcs), 2027–2032
Table 35. Europe Drug Labels Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Drug Labels Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Drug Labels Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Drug Labels Sales by Region (K Pcs), 2021–2026
Table 39. Asia Pacific Drug Labels Sales by Region (K Pcs), 2027–2032
Table 40. Asia Pacific Drug Labels Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Drug Labels Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Drug Labels Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Drug Labels Sales by Country (K Pcs), 2021–2026
Table 44. Latin America Drug Labels Sales by Country (K Pcs), 2027–2032
Table 45. Latin America Drug Labels Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Drug Labels Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Drug Labels Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Drug Labels Sales by Country (K Pcs), 2021–2026
Table 49. Middle East and Africa Drug Labels Sales by Country (K Pcs), 2027–2032
Table 50. Middle East and Africa Drug Labels Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Drug Labels Revenue by Country (US$ Million), 2027–2032
Table 52. Global Drug Labels Sales (K Pcs) by Type (2021–2026)
Table 53. Global Drug Labels Sales (K Pcs) by Type (2027–2032)
Table 54. Global Drug Labels Sales Market Share by Type (2021–2026)
Table 55. Global Drug Labels Sales Market Share by Type (2027–2032)
Table 56. Global Drug Labels Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Drug Labels Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Drug Labels Revenue Market Share by Type (2021–2026)
Table 59. Global Drug Labels Revenue Market Share by Type (2027–2032)
Table 60. Global Drug Labels Price (US$/Pc) by Type (2021–2026)
Table 61. Global Drug Labels Price (US$/Pc) by Type (2027–2032)
Table 62. Global Drug Labels Sales (K Pcs) by Application (2021–2026)
Table 63. Global Drug Labels Sales (K Pcs) by Application (2027–2032)
Table 64. Global Drug Labels Sales Market Share by Application (2021–2026)
Table 65. Global Drug Labels Sales Market Share by Application (2027–2032)
Table 66. Global Drug Labels Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Drug Labels Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Drug Labels Revenue Market Share by Application (2021–2026)
Table 69. Global Drug Labels Revenue Market Share by Application (2027–2032)
Table 70. Global Drug Labels Price (US$/Pc) by Application (2021–2026)
Table 71. Global Drug Labels Price (US$/Pc) by Application (2027–2032)
Table 72. PDC (Brady) Company Information
Table 73. PDC (Brady) Description and Business Overview
Table 74. PDC (Brady) Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 75. PDC (Brady) Drug Labels Product
Table 76. PDC (Brady) Recent Developments/Updates
Table 77. 3M Company Information
Table 78. 3M Description and Business Overview
Table 79. 3M Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 80. 3M Drug Labels Product
Table 81. 3M Recent Developments/Updates
Table 82. RR Donnelley & Sons (RRD) Company Information
Table 83. RR Donnelley & Sons (RRD) Description and Business Overview
Table 84. RR Donnelley & Sons (RRD) Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 85. RR Donnelley & Sons (RRD) Drug Labels Product
Table 86. RR Donnelley & Sons (RRD) Recent Developments/Updates
Table 87. LabTAG Company Information
Table 88. LabTAG Description and Business Overview
Table 89. LabTAG Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 90. LabTAG Drug Labels Product
Table 91. LabTAG Recent Developments/Updates
Table 92. Tapecon Company Information
Table 93. Tapecon Description and Business Overview
Table 94. Tapecon Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 95. Tapecon Drug Labels Product
Table 96. Tapecon Recent Developments/Updates
Table 97. Avery Dennison Company Information
Table 98. Avery Dennison Description and Business Overview
Table 99. Avery Dennison Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 100. Avery Dennison Drug Labels Product
Table 101. Avery Dennison Recent Developments/Updates
Table 102. CCL Industries Company Information
Table 103. CCL Industries Description and Business Overview
Table 104. CCL Industries Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 105. CCL Industries Drug Labels Product
Table 106. CCL Industries Recent Developments/Updates
Table 107. CCL Healthcare Company Information
Table 108. CCL Healthcare Description and Business Overview
Table 109. CCL Healthcare Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 110. CCL Healthcare Drug Labels Product
Table 111. CCL Healthcare Recent Developments/Updates
Table 112. Multi-Color Corporation (MCC) Company Information
Table 113. Multi-Color Corporation (MCC) Description and Business Overview
Table 114. Multi-Color Corporation (MCC) Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 115. Multi-Color Corporation (MCC) Drug Labels Product
Table 116. Multi-Color Corporation (MCC) Recent Developments/Updates
Table 117. Autajon Group Company Information
Table 118. Autajon Group Description and Business Overview
Table 119. Autajon Group Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 120. Autajon Group Drug Labels Product
Table 121. Autajon Group Recent Developments/Updates
Table 122. Smurfit Westrock Company Information
Table 123. Smurfit Westrock Description and Business Overview
Table 124. Smurfit Westrock Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 125. Smurfit Westrock Drug Labels Product
Table 126. Smurfit Westrock Recent Developments/Updates
Table 127. Xerafy Company Information
Table 128. Xerafy Description and Business Overview
Table 129. Xerafy Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 130. Xerafy Drug Labels Product
Table 131. Xerafy Recent Developments/Updates
Table 132. Cymmetrik Company Information
Table 133. Cymmetrik Description and Business Overview
Table 134. Cymmetrik Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 135. Cymmetrik Drug Labels Product
Table 136. Cymmetrik Recent Developments/Updates
Table 137. Schreiner Group (Schreiner MediPharm) Company Information
Table 138. Schreiner Group (Schreiner MediPharm) Description and Business Overview
Table 139. Schreiner Group (Schreiner MediPharm) Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 140. Schreiner Group (Schreiner MediPharm) Drug Labels Product
Table 141. Schreiner Group (Schreiner MediPharm) Recent Developments/Updates
Table 142. SATO Holdings Company Information
Table 143. SATO Holdings Description and Business Overview
Table 144. SATO Holdings Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 145. SATO Holdings Drug Labels Product
Table 146. SATO Holdings Recent Developments/Updates
Table 147. DYMO Corporation Company Information
Table 148. DYMO Corporation Description and Business Overview
Table 149. DYMO Corporation Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 150. DYMO Corporation Drug Labels Product
Table 151. DYMO Corporation Recent Developments/Updates
Table 152. Nosco Company Information
Table 153. Nosco Description and Business Overview
Table 154. Nosco Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 155. Nosco Drug Labels Product
Table 156. Nosco Recent Developments/Updates
Table 157. Resource Label Group Company Information
Table 158. Resource Label Group Description and Business Overview
Table 159. Resource Label Group Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 160. Resource Label Group Drug Labels Product
Table 161. Resource Label Group Recent Developments/Updates
Table 162. Royal Label Company Information
Table 163. Royal Label Description and Business Overview
Table 164. Royal Label Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 165. Royal Label Drug Labels Product
Table 166. Royal Label Recent Developments/Updates
Table 167. PRO-TECH Design Company Information
Table 168. PRO-TECH Design Description and Business Overview
Table 169. PRO-TECH Design Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 170. PRO-TECH Design Drug Labels Product
Table 171. PRO-TECH Design Recent Developments/Updates
Table 172. Imprint Enterprises Company Information
Table 173. Imprint Enterprises Description and Business Overview
Table 174. Imprint Enterprises Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 175. Imprint Enterprises Drug Labels Product
Table 176. Imprint Enterprises Recent Developments/Updates
Table 177. JN White Company Information
Table 178. JN White Description and Business Overview
Table 179. JN White Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 180. JN White Drug Labels Product
Table 181. JN White Recent Developments/Updates
Table 182. Suzhou Thunder Weiye Information Technology Co., Ltd. Company Information
Table 183. Suzhou Thunder Weiye Information Technology Co., Ltd. Description and Business Overview
Table 184. Suzhou Thunder Weiye Information Technology Co., Ltd. Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 185. Suzhou Thunder Weiye Information Technology Co., Ltd. Drug Labels Product
Table 186. Suzhou Thunder Weiye Information Technology Co., Ltd. Recent Developments/Updates
Table 187. Zaosin Company Information
Table 188. Zaosin Description and Business Overview
Table 189. Zaosin Drug Labels Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)
Table 190. Zaosin Drug Labels Product
Table 191. Zaosin Recent Developments/Updates
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Drug Labels Distributors List
Table 195. Drug Labels Customers List
Table 196. Drug Labels Market Trends
Table 197. Drug Labels Market Drivers
Table 198. Drug Labels Market Challenges
Table 199. Drug Labels Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
Table 203. Authors List of This Report
List of Figures
Figure 1. Product Picture of Drug Labels
Figure 2. Global Drug Labels Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Drug Labels Market Share by Type: 2025 & 2032
Figure 4. Paper Label Product Picture
Figure 5. Plastic Label Product Picture
Figure 6. Composite Material Label Product Picture
Figure 7. Special Material Label Product Picture
Figure 8. Global Drug Labels Market Value by Technology Type (US$ Million), 2021–2032
Figure 9. Global Drug Labels Market Share by Technology Type: 2025 vs 2032
Figure 10. Thermal Transfer Labels Product Picture
Figure 11. Cryogenic Labels Product Picture
Figure 12. Chemical-Resistant Labels Product Picture
Figure 13. Others Product Picture
Figure 14. Global Drug Labels Market Value by Adhesive Type (US$ Million), 2021–2032
Figure 15. Global Drug Labels Market Share by Adhesive Type: 2025 vs 2032
Figure 16. Permanent Adhesives Product Picture
Figure 17. Removable Adhesives Product Picture
Figure 18. Global Drug Labels Market Value by Application (US$ Million), 2021–2032
Figure 19. Global Drug Labels Market Share by Application: 2025 & 2032
Figure 20. Pharmaceutical Factory
Figure 21. Hospital
Figure 22. Others
Figure 23. Global Drug Labels Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Drug Labels Market Size (US$ Million), 2021–2032
Figure 25. Global Drug Labels Sales (K Pcs), 2021–2032
Figure 26. Global Drug Labels Average Price (US$/Pc), 2021–2032
Figure 27. Drug Labels Report Years Considered
Figure 28. Drug Labels Sales Share by Manufacturers in 2025
Figure 29. Global Drug Labels Revenue Share by Manufacturers in 2025
Figure 30. Top 5 and Top 10 Global Drug Labels Players: Market Share by Revenue in Drug Labels in 2025
Figure 31. Drug Labels Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 32. Global Drug Labels Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 33. North America Drug Labels Sales Market Share by Country (2021–2032)
Figure 34. North America Drug Labels Revenue Market Share by Country (2021–2032)
Figure 35. U.S. Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Canada Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Europe Drug Labels Sales Market Share by Country (2021–2032)
Figure 38. Europe Drug Labels Revenue Market Share by Country (2021–2032)
Figure 39. Germany Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. France Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. U.K. Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Italy Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Russia Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Asia Pacific Drug Labels Sales Market Share by Region (2021–2032)
Figure 45. Asia Pacific Drug Labels Revenue Market Share by Region (2021–2032)
Figure 46. China Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Japan Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. South Korea Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. India Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Australia Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Taiwan Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Indonesia Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Thailand Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Malaysia Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Philippines Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Latin America Drug Labels Sales Market Share by Country (2021–2032)
Figure 57. Latin America Drug Labels Revenue Market Share by Country (2021–2032)
Figure 58. Mexico Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Brazil Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Argentina Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Middle East and Africa Drug Labels Sales Market Share by Country (2021–2032)
Figure 62. Middle East and Africa Drug Labels Revenue Market Share by Country (2021–2032)
Figure 63. Turkey Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. Saudi Arabia Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. U.A.E Drug Labels Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. Global Sales Market Share of Drug Labels by Type (2021–2032)
Figure 67. Global Revenue Market Share of Drug Labels by Type (2021–2032)
Figure 68. Global Drug Labels Price (US$/Pc) by Type (2021–2032)
Figure 69. Global Sales Market Share of Drug Labels by Application (2021–2032)
Figure 70. Global Revenue Market Share of Drug Labels by Application (2021–2032)
Figure 71. Global Drug Labels Price (US$/Pc) by Application (2021–2032)
Figure 72. Drug Labels Value Chain
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
